Abstract: Human epidermal growth factor receptor-2（HER-2） positive inflammatory breast cancer is a very aggressive type of inflammatory breast cancer（IBC） with HER-2 over-expression or amplified. Clinically，such cancer is more aggressive and characterized by rapid local and systemic progression and overlying skin inflammation or discoloration without ulceration. With poor prognosis, but，combinations of neo-adjuvant systemic chemotherapy， surgery and radiation therapy，especially molecular targeted therapy can drastically alter the natural course of this disease. This article reviews the progress in molecular targeted therapy for HER-2 positive IBC in recent years.